{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:50:12Z","timestamp":1780638612319,"version":"3.54.1"},"reference-count":50,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T00:00:00Z","timestamp":1340064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Obesity is often associated with chronic inflammatory state which contributes to the development of insulin resistance (<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>) and type 2 diabetes mellitus (<jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>). This study investigated the effects of single and combined administration of atorvastatin (<jats:styled-content style=\"fixed-case\">ATOR<\/jats:styled-content>, lipid\u2010lowering drug) and losartan (<jats:styled-content style=\"fixed-case\">LOS<\/jats:styled-content>, angiotensin receptor antagonist) on metabolic disorders and inflammatory status that are implicated in the development of <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> with the use of pioglitazone (<jats:styled-content style=\"fixed-case\">PIO<\/jats:styled-content>) as a standard antidiabetic drug. <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> was induced in male rats by high\u2010fat diet (<jats:styled-content style=\"fixed-case\">HFD<\/jats:styled-content>) feeding for 16\u00a0weeks. Oral administrations of <jats:styled-content style=\"fixed-case\">ATOR<\/jats:styled-content> (10\u00a0mg\/kg), <jats:styled-content style=\"fixed-case\">LOS<\/jats:styled-content> (20\u00a0mg\/kg), <jats:styled-content style=\"fixed-case\">PIO<\/jats:styled-content> (3\u00a0mg\/kg), their binary combinations, or vehicle were started in the last 4\u00a0weeks. Fasting serum glucose, oral glucose tolerance, fasting serum insulin, <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>, serum lipid profile, serum <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 and body composition index were determined. Results showed that all drugs and their combinations had positive impact effect on all measured parameters, and better results were achieved from binary drug combinations than administration of each drug alone. Combination of <jats:styled-content style=\"fixed-case\">PIO<\/jats:styled-content> with either <jats:styled-content style=\"fixed-case\">ATOR<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">LOS<\/jats:styled-content> provided better improvements on <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>\u2010associated metabolic abnormalities and inflammatory status with respect to each drug alone. However, the most pronounced effects of drugs and their combinations regarding the above parameters were attributed to <jats:styled-content style=\"fixed-case\">LOS<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">PIO<\/jats:styled-content> combination. In conclusion, this study indicates that combination of <jats:styled-content style=\"fixed-case\">ATOR<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">PIO<\/jats:styled-content> and, in particular, <jats:styled-content style=\"fixed-case\">LOS<\/jats:styled-content>\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">PIO<\/jats:styled-content> can be used as promising effective therapies in the management of <jats:styled-content style=\"fixed-case\">HFD<\/jats:styled-content>\u2010induced <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>. This concept may be attributed to the combined effects of the respective monotherapies to improve lipid profile, insulin sensitivity, and <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1 level.<\/jats:p>","DOI":"10.1111\/j.1472-8206.2012.01048.x","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T14:23:03Z","timestamp":1337610183000},"page":"489-497","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative study between atorvastatin and losartan on high fat diet\u2010induced type 2 diabetes mellitus in rats"],"prefix":"10.1111","volume":"27","author":[{"given":"Ahmed A.","family":"Mourad","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy Minia University  El\u2010Minia Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gehan H.","family":"Heeba","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy Minia University  El\u2010Minia Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Taye","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy Minia University  El\u2010Minia Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"El\u2010Moselhy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy Minia University  El\u2010Minia Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,19]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.6.1615"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20920"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01058.2004"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.02.023"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.11.007"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117899"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(00)00272-1"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200319451"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117936"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(03)00052-2"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.134.6.8194485"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29069"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2007.11.051"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00125.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/hq1101.098486"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31811f3fd0"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/hq0202.104081"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2007.011"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000126501.34994.96"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000125142.41703.64"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2010.05.004"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199907000-00005"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2011.02.004"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2008.07.005"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-8-32"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.0912"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.30.5.1054"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(02)00367-2"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(99)00352-4"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.5.1319"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2006.06.004"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051218"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.9.2094"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29024"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2008.01.006"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02684000"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00309-8"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00090.2004"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.293"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000036448.44066.53"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1995"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.6.1699"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2007.04.001"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000127955.36250.65"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-5678fje"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2010.79"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2004.11.004"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.21.2131"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1472-8206.2012.01048.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1472-8206.2012.01048.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T03:51:24Z","timestamp":1696305084000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1472-8206.2012.01048.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,19]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/j.1472-8206.2012.01048.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1472-8206.2012.01048.x","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,19]]},"assertion":[{"value":"2012-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}